⁸⁹Zr-trastuzumab PET supports clinical decision making in breast cancer patients, when HER2 status cannot be determined by standard work up.

ABSTRACT:

Background

Up-to-date information on human epidermal growth factor receptor 2 (HER2) status in breast cancer (BC) is important, as expression can vary during the course of the disease, necessitating anti-HER2 therapy adjustments. Repeat biopsies, however, are not always possible. In this feasibility trial we assessed whether ⁸⁹Zr-trastuzumab PET could support diagnostic understanding and aid clinical decision making, when HER2 status could not be determined by standard work up. Additionally, HER2 status on circulating tumour cells (CTCs) was assessed.

Patients and methods

⁸⁹Zr-trastuzumab PET was performed in patients if disease HER2 status remained unclear after standard work up (bone scan, ¹⁸F-FDG PET, CT and if feasible a biopsy). PET resu

SUBMITTER: Bensch F 

PROVIDER: S-EPMC6208812 | biostudies-literature | 2018 Dec

REPOSITORIES: biostudies-literature